The Journal of Experimental Medicine published Phase 2 results last week showing that Novartis’ enzyme-blocking cancer drug imatinib cleared malaria parasites from 100% of treated adult Vietnamese men in three days when used in combination with standard of care (piperaquine plus dihydroartemisinin).

In contrast, 33% of trial participants who received only standard of care without the imatinib supplement experienced delayed parasite clearance rates—a precursor to and an indicator of…


Thirteen leading pharma companies released second-quarter 2021 financial results in July, while one Japanese firm reported first-quarter results for the fiscal year ending in March. (Figures exclude exchange rate and portfolio changes where applicable.)
Pfizer’s revenues soared 86% in the second quarter to $19 billion, beating consensus estimates of $17.5 billion. The Comirnaty Covid-19 vaccine led the results with $7.8 billion in sales. Based on contracts signed through mid-…

Moderna announced last week its launch of a foundation to promote “public health, healthcare and educational opportunities,” with an initial endowment of $50 million. The Moderna Charitable Foundation is the first public social good commitment for the maker of the blockbuster Covid-19 vaccine.

Meanwhile, Novartis last week announced a 10-year collaboration with multiple U.S.-based historically Black colleges and universities (HBCUs) and HCBU medical schools to co-create programs that…


The state of the hunt: 

Moderna’s vaccine showed high efficacy in adolescents.
  U.S. regulators cleared a monoclonal antibody from GSK and Vir for emergency use.
  Sanofi and GSK launched the Phase 3 trial of their vaccine candidate.   Approved or authorized vaccines

Moderna touts data for teens: Less than two months after Pfizer and BioNTech boasted of their mRNA-based jab’s 100% efficacy in adolescents, Moderna shared almost identical news. The Massachusetts-…

Twelve leading pharma companies released first-quarter 2021 financial results in April. (Figures exclude exchange rate and portfolio changes where applicable.)

Leading the round, Abbott’s first-quarter worldwide sales jumped 32.9% over last year’s to $10.5 billion, missing consensus estimates by 3.5%. Its diagnostics business continued to boom, with strong Covid-19 test sales driving 115% growth. The company said it has delivered nearly 700 million Covid-19 tests since the start of the…

The state of the hunt:

Moderna began clinical trials of its vaccine in children.
  New vaccines from Iran and Vietnam entered human trials, and a Cuban shot reached Phase 3.
  France limited use of AstraZeneca’s vaccine to people 55 or older.



Approved or authorized vaccines
AZ jab is safe, EMA reaffirms—but will uptake suffer? A European Medicines Agency (EMA) risk assessment committee concluded a preliminary review…

The state of the hunt:

J&J’s vaccine became the first single-dose Covid-19 jab to receive EUL from the World Health Organization.
  A growing list of countries—including at least one COVAX AMC participant—suspended their rollouts of AstraZeneca’s vaccine over safety concerns.
  Monoclonal antibodies from Lilly and a separate mAb from GSK and Vir substantially cut the risk of hospitalization or death in people with mild or moderate Covid-19 at high risk of progression…

The state of the hunt:

Serum Institute of India will export Covishield doses to the United Kingdom.
  COVAX unveiled initial vaccine allocations, and numerous COVAX participants received their first shipments and began administering jabs.
  Bharat Biotech’s Covaxin demonstrated 81% efficacy against symptomatic disease in an interim Phase 3 analysis.



Approved or authorized vaccines
U.S. regulators completed their signoff…

Adjuvant Capital announced last week a $300 million Global Health Technology Fund focused on accelerating the development of medical innovations for “historically overlooked public health challenges.”

The New York-based social impact investor noted in its press release that it has already backed 14 companies, requiring each to make products broadly accessible to people in low- and middle-income countries. Adjuvant’s “young portfolio” includes investments in companies addressing…

The industry-backed AMR Action Fund announced new investments last week totaling more than $140 million from the Boehringer Ingelheim Foundation, the European Investment Bank and Wellcome Trust. It also appointed Henry Skinner—a venture capitalist and microbiologist who once served as a managing director of Novartis Venture Fund—as its CEO.

Skinner told STAT that the billion-dollar fund, which seeks to bring two to four new antibiotics to market by 2030, is “a bridge investment” to buy…